Citations

Clear

1011 citation(s) found for "Barry, WT".

Choosing Ceftazidime/Avibactam and Ceftolozane/Tazobactam as Empiric Therapies against Pseudomonas aeruginosa (Pa) using Rapid Molecular Diagnostics (RMDs): PRIMERS IV
Tran, Thuy Tien T., Hujer, Andrea M. , Hill, Carol , Hujer, Kristine M., Mediavilla, José R. , Kreiswirth, Barry N , Pérez, Federico , Sampath, Rangarajan , Marzan, Christine, Fowler, Vance G. , Chambers, Henry F. , Evans, Scott , Manca, Claudia , Domitrovic, Tatiana , Patel, Robin , Jacobs, Michael R. , Chen, Liang , Hall, Thomas, Fowler, Vance G. , Bonomo, Robert A.

Mayo Clinic

Open Forum Infectious Diseases | February 1, 2017 | Volume: 3 | Issue: suppl_1 | Pages: No page available

10.1093/ofid/ofw172.1598 Get It

Long-term cardiovascular changes following creation of arteriovenous fistula in patients with end stage renal disease
Reddy, Yogesh N.V. , Obokata, Masaru , Dean, Patrick G. , Melenovský, Vojtěch , Nath, Karl A. , Borlaug, Barry A. , Nishimura, Rick , Borlaug, Barry A , Obokata, Masaru , Melenovský, Vojtěch

Mayo Clinic

European Heart Journal | January 30, 2017 | Volume: 38 | Issue: 24 | Pages: 1913-1923

10.1093/eurheartj/ehx045 | PMID 28329100 Get It

Abstract Aims Short-term studies have reported left ventricular (LV) dilatation following surgical creation of arteriovenous fistulas (AVF) or arteriovenous grafts (AVGs), but chronic cardiac structural and functional changes have not been examined or related to clinical outcomes following AVF/AVG. We sought to characterize the long-term changes in cardiac structure and function in patients undergoing shunt creation for haemodialysis. Methods and results A retrospective analysis was performed of patients undergoing echocardiography before and after surgical AVF/AVG creation for the initiation of haemodialysis. 137 patients underwent echocardiographic examinations prior to AVF and 2.6 years (median) after AVF creation. Following AVF and dialysis initiation, there were reductions in blood pressure, body weight and estimated plasma volume coupled with modest reverse LV remodelling. In contrast, AVF/AVG creation was associated with significant right ventricular (RV) dilatation and deterioration in RV function. Incident heart failure (HF) developed in 43% of patients in tandem with greater RV remodeling. The development of RV dilation following surgical AVF/AVG was independently associated with increased risk of death [HR 3.9, 95% CI (1.7–9.2), P = 0.001]. Conclusion In long-term follow-up, RV remodelling and dysfunction develop following AVF/AVG creation and dialysis initiation, despite improved control of LV pressure load through dialysis. Deleterious effects on right heart structure and function are coupled with development of incident HF and increased risk of death. Further study is required to identify patients at greatest risk for detrimental AVF/AVG changes who may benefit from alternate forms of dialysis or potentially ligation of existing AVF.
The Charter on Professionalism for Health Care Organizations
Egener, Barry, Mason, Diana J. , McDonald, Walter J., Okun, Sally , Gaines, Martha E., Rosof, Bernie M., Gullen, David, Andresen, May-Lynn, Egener, Barry E, Fleming, David A. , Rosof, Bernard M., Andresen, May-Lynn

Mayo Clinic

Academic Medicine | January 11, 2017 | Volume: 92 | Issue: 8 | Pages: 1091-1099

10.1097/acm.0000000000001561 | PMID 28079726 Get It

In 2002, the Physician Charter on Medical Professionalism was published to provide physicians with guidance for decision making in a rapidly changing environment. Feedback from physicians indicated that they were unable to fully live up to the principles in the 2002 charter partly because of their employing or affiliated health care organizations. A multistakeholder group has developed a Charter on Professionalism for Health Care Organizations, which may provide more guidance than charters for individual disciplines, given the current structure of health care delivery systems. This article contains the Charter on Professionalism for Health Care Organizations, as well as the process and rationale for its development. For hospitals and hospital systems to effectively care for patients, maintain a healthy workforce, and improve the health of populations, they must attend to the four domains addressed by the Charter: patient partnerships, organizational culture, community partnerships, and operations and business practices. Impacting the social determinants of health will require collaboration among health care organizations, government, and communities. Transitioning to the model hospital described by the Charter will challenge historical roles and assumptions of both its leadership and staff. While the Charter is aspirational, it also outlines specific institutional behaviors that will benefit both patients and workers. Lastly, this article considers obstacles to implementing the Charter and explores avenues to facilitate its dissemination.
Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction
Obokata, Masaru , Kane, Garvan C. , Reddy, Yogesh N.V. , Olson, Thomas P. , Melenovský, Vojtěch , Borlaug, Barry A. , Nishimura, Rick , Borlaug, Barry A , Obokata, Masaru , Melenovský, Vojtěch

Mayo Clinic

Circulation | December 30, 2016 | Volume: 135 | Issue: 9 | Pages: 825-838

10.1161/circulationaha.116.024822 | PMID 28039229 Get It

Background: Diagnosis of heart failure with preserved ejection fraction (HFpEF) is challenging and relies largely on demonstration of elevated cardiac filling pressures (pulmonary capillary wedge pressure). Current guidelines recommend use of natriuretic peptides (N-terminal pro-B type natriuretic peptide) and rest/exercise echocardiography (E/e′ ratio) to make this determination. Data to support this practice are conflicting. Methods: Simultaneous echocardiographic-catheterization studies were prospectively conducted at rest and during exercise in subjects with invasively proven HFpEF (n=50) and participants with dyspnea but no identifiable cardiac pathology (n=24). Results: N-Terminal pro-B type natriuretic peptide levels were below the level considered to exclude disease (≤125 pg/mL) in 18% of subjects with HFpEF. E/e′ ratio was correlated with directly measured pulmonary capillary wedge pressure at rest ( r =0.63, P <0.0001) and during exercise ( r =0.57, P <0.0001). Although specific, current guidelines were poorly sensitive, identifying only 34% to 60% of subjects with invasively proven HFpEF on the basis of resting echocardiographic data alone. Addition of exercise echocardiographic data (E/e′ ratio>14) improved sensitivity (to 90%) and thus negative predictive value, but decreased specificity (71%). Conclusions: Currently proposed HFpEF diagnostic guidelines on the basis of resting data are poorly sensitive. Adding exercise E/e′ data improves sensitivity and negative predictive value but compromises specificity, suggesting that exercise echocardiography may help rule out HFpEF. These results question the accuracy of current approaches to exclude HFpEF on the basis of resting data alone and reinforce the value of exercise testing using invasive and noninvasive hemodynamic assessments to definitively confirm or refute the diagnosis of HFpEF. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique Identifier: NCT01418248.
Advancing Diagnostics to Address Antibacterial Resistance: The Diagnostics and Devices Committee of the Antibacterial Resistance Leadership Group
Tsalik, Ephraim L. , Petzold, Elizabeth , Kreiswirth, Barry N. , Banerjee, Ritu , Lautenbach, Ebbing , Hanson, Kimberly E. , Klausner, Jeffrey D. , Patel, Robin , Group, of the Antibacterial Resistance Leadership, Kreiswirth, Barry N , Bonomo, Robert A. , Evans, Scott , Group, of the Antibacterial Resistance Leadership, Patel, Robin , Evans, Scott R , Hanson, Kimberly

Mayo Clinic

Clinical Infectious Diseases | December 8, 2016 | Volume: 64 | Issue: suppl_1 | Pages: S41-S47

10.1093/cid/ciw831 | PMID 28350903 Get It

Sildenafil, Unbridled Optimism, and Heart Failure with Preserved Ejection Fraction
Reddy, Yogesh N.V. , Borlaug, Barry A. , Nishimura, Rick , Borlaug, Barry A

Mayo Clinic

European Journal of Heart Failure | November 21, 2016 | Volume: 19 | Issue: 1 | Pages: 126-128

10.1002/ejhf.690 | PMID 27873389 Get It

Data and Safety Monitoring Board Evaluation and Management of a Renal Adverse Event Signal in TOPCAT
Assmann, Susan F., Linas, Stuart L., Rice, Madeline Murguia , Singh, Steven , Boineau, Robin , McKinlay, Sonja M., Greenberg, Barry , Bristow, Michael R. , Sharma, Kavita , Gersh, Bernard J. , Grady, Christine

Mayo Clinic

European Journal of Heart Failure | November 21, 2016 | Volume: 19 | Issue: 4 | Pages: 457-465

10.1002/ejhf.686 | PMID 27873428 Get It

Abstract Clinical trial Data and Safety Monitoring Boards (DSMBs) have a primary obligation of ensuring study participant safety, while maintaining trial integrity. The role of DSMBs is expanding, and ideally should include post-hoc reporting of deliberative processes related to clinically important safety issues or factors that could impact on future trial designs. We describe how the TOPCAT DSMB detected, investigated, and adjudicated an unexpectedly large renal adverse event signal midway through the trial, and offer general guidelines for dealing with similar unanticipated occurrences in future trials. The detection of a greater than expected incidence of deterioration in renal function, occurring in 6.1% of patients in the spironolactone arm compared with 3.9% in the placebo arm (P = 0.009), led to an in-depth DSMB review of associated study medication withdrawals and adverse events. The trial continued uninterrupted throughout the review, which reached the conclusions that spironolactone-associated renal dysfunction did not compromise overall patient safety or interfere with a perceived efficacy signal. Although no discrete mechanism for the spironolactone-associated renal adverse event signal was identified, likely possibilities are discussed. In clinical trials, DSMBs and co-ordinating centres should have the resources to detect, investigate, and adjudicate unexpected safety issues, with goals of ensuring patient safety and preserving the potential for detection of therapeutic effectiveness. In TOPCAT, spironolactone-associated renal dysfunction emerged as a potentially trial-threatening adverse event and, although clinically important, did not lead to compromise of patient safety, trial interruption, termination, or apparent loss of treatment effectiveness.
Introducing Essential Oils into Pediatric and Other Practices at an Academic Medical Center
Conlon, Patricia M. , Haack, Kristen M., Rodgers, Nancy J., Dion, Liza J., Cambern, Kari L., Rohlik, Gina, Nelson, Dawn E., Barry, Tracy A., Ayres, Sara , Cutshall, Susanne M. , Rohlik, Gina M, Ayres, Sara J

Mayo Clinic

Journal of Holistic Nursing | November 11, 2016 | Volume: 35 | Issue: 4 | Pages: 389-396

10.1177/0898010116677400 | PMID 27837082 Get It

Aromatherapy is an integrative intervention that uses essential oils to address symptom management, potentially as a first-line intervention or as a complement to other medical treatments. Aromatherapy is gaining widespread acceptance and increased scientific evidence of efficacy. Integrative and holistic nursing care uses integrative therapies such as aromatherapy and the principle of moving from a less invasive intervention to a more invasive intervention according to patient needs, symptoms, and preferences. Aromatherapy is often provided as a minimally invasive, independent, and integrative nursing intervention. This article describes the process used to introduce essential oils into practices at a large Midwestern academic medical center.
Replicating Single-Cycle Adenovirus Vectors Generate Amplified Influenza Vaccine Responses
Crosby, Catherine M. , Matchett, William E. , Anguiano-Zarate, Stephanie S., Parks, Christopher A. , Pease, Larry R. , Barry, Michael A. , Weaver, Eric A. , Webby, Richard J. , Weaver, Eric A , Barry, Michael A

Mayo Clinic

Journal of Virology | November 3, 2016 | Volume: 91 | Issue: 2 | Pages: No page available

10.1128/jvi.00720-16 | PMID 27807231 Get It

ABSTRACT Head-to-head comparisons of conventional influenza vaccines with adenovirus (Ad) gene-based vaccines demonstrated that these viral vectors can mediate more potent protection against influenza virus infection in animal models. In most cases, Ad vaccines are engineered to be replication-defective (RD-Ad) vectors. In contrast, replication-competent Ad (RC-Ad) vaccines are markedly more potent but risk causing adenovirus diseases in vaccine recipients and health care workers. To harness antigen gene replication but avoid production of infectious virions, we developed “single-cycle” adenovirus (SC-Ad) vectors. Previous work demonstrated that SC-Ads amplify transgene expression 100-fold and produce markedly stronger and more persistent immune responses than RD-Ad vectors in Syrian hamsters and rhesus macaques. To test them as potential vaccines, we engineered RD and SC versions of adenovirus serotype 6 (Ad6) to express the hemagglutinin (HA) gene from influenza A/PR/8/34 virus. We show here that it takes approximately 33 times less SC-Ad6 than RD-Ad6 to produce equal amounts of HA antigen in vitro . SC-Ad produced markedly higher HA binding and hemagglutination inhibition (HAI) titers than RD-Ad in Syrian hamsters. SC-Ad-vaccinated cotton rats had markedly lower influenza titers than RD-Ad-vaccinated animals after challenge with influenza A/PR/8/34 virus. These data suggest that SC-Ads may be more potent vaccine platforms than conventional RD-Ad vectors and may have utility as “needle-free” mucosal vaccines. IMPORTANCE Most adenovirus vaccines that are being tested are replication-defective adenoviruses (RD-Ads). This work describes testing newer single-cycle adenovirus (SC-Ad) vectors that replicate transgenes to amplify protein production and immune responses. We show that SC-Ads generate markedly more influenza virus hemagglutinin protein and require substantially less vector to generate the same immune responses as RD-Ad vectors. SC-Ads therefore hold promise to be more potent vectors and vaccines than current RD-Ad vectors.
Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III
Hujer, Andrea M. , Jiang, Hongyu , Hill, Carol , Hujer, Kristine M., Mediavilla, José R. , Tran, Thuy Tien T., Higgins, Paul G. , Kreiswirth, Barry N. , Patel, Robin , Chen, Liang , Sampath, Rangarajan , Marzan, Christine, Fowler, Vance G. , Chambers, Henry F. , Sampath, Rangarajan , Evans, Scott , Manca, Claudia , Domitrovic, Tatiana , Seifert, Harald , Kreiswirth, Barry N , Jacobs, Michael R. , Chen, Liang , Hall, Thomas A. , Fowler, Vance G. , Bonomo, Robert A. , Patel, Robin , Evans, Scott R

Mayo Clinic

Journal of Clinical Microbiology | October 26, 2016 | Volume: 55 | Issue: 1 | Pages: 134-144

10.1128/jcm.01524-16 | PMID 27795336 Get It

ABSTRACT The widespread dissemination of carbapenem-resistant Acinetobacter spp. has created significant therapeutic challenges. At present, rapid molecular diagnostics (RMDs) that can identify this phenotype are not commercially available. Two RMD platforms, PCR combined with electrospray ionization mass spectrometry (PCR/ESI-MS) and molecular beacons (MB), for detecting genes conferring resistance/susceptibility to carbapenems in Acinetobacter spp. were evaluated. An archived collection of 200 clinical Acinetobacter sp. isolates was tested. Predictive values for susceptibility and resistance were estimated as a function of susceptibility prevalence and were based on the absence or presence of beta-lactamase ( bla ) NDM, VIM, IMP, KPC, and OXA carbapenemase genes (e.g., bla OXA-23 , bla OXA-24/40 , and bla OXA-58 found in this study) against the reference standard of MIC determinations. According to the interpretation of MICs, 49% ( n = 98) of the isolates were carbapenem resistant (as defined by either resistance or intermediate resistance to imipenem). The susceptibility sensitivities (95% confidence interval [CI]) for imipenem were 82% (74%, 89%) and 92% (85%, 97%) for PCR/ESI-MS and MB, respectively. Resistance sensitivities (95% CI) for imipenem were 95% (88%, 98%) and 88% (80%, 94%) for PCR/ESI-MS and MB, respectively. PRIMERS III establishes that RMDs can discriminate between carbapenem resistance and susceptibility in Acinetobacter spp. In the context of a known prevalence of resistance, SPVs and RPVs can inform clinicians regarding the best choice for empiric antimicrobial therapy against this multidrug-resistant pathogen.